title: Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement.
abstract: Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the United States, accounting for 1 of every 3 deaths among adults.
  
  
  
  To update the 2008 US Preventive Services Task Force (USPSTF) recommendation on screening for lipid disorders in adults.
  
  
  
  The USPSTF reviewed the evidence on the benefits and harms of screening for and treatment of dyslipidemia in adults 21 years and older; the benefits and harms of statin use in reducing CVD events and mortality in adults without a history of CVD events; whether the benefits of statin use vary by subgroup, clinical characteristics, or dosage; and the benefits of various treatment strategies in adults 40 years and older without a history of CVD events.
  
  
  
  The USPSTF recommends initiating use of low- to moderate-dose statins in adults aged 40 to 75 years without a history of CVD who have 1 or more CVD risk factors (dyslipidemia, diabetes, hypertension, or smoking) and a calculated 10-year CVD event risk of 10% or greater (B recommendation). The USPSTF recommends that clinicians selectively offer low- to moderate-dose statins to adults aged 40 to 75 years without a history of CVD who have 1 or more CVD risk factors and a calculated 10-year CVD event risk of 7.5% to 10% (C recommendation). The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of initiating statin use in adults 76 years and older (I statement).
authors.affiliation: University of California, San Francisco.
authors.forename: Kirsten
authors.initials: K
authors.lastname: Bibbins-Domingo
authors.affiliation: Group Health Research Institute, Seattle, Washington.
authors.forename: David C
authors.initials: DC
authors.lastname: Grossman
authors.affiliation: University of Iowa, Iowa City.
authors.forename: Susan J
authors.initials: SJ
authors.lastname: Curry
authors.affiliation: Columbia University, New York, New York.
authors.forename: Karina W
authors.initials: KW
authors.lastname: Davidson
authors.affiliation: State University of New York Upstate Medical University, Syracuse.
authors.forename: John W
authors.initials: JW
authors.lastname: Epling
authors.affiliation: Pima County Department of Health, Tucson, Arizona.
authors.forename: Francisco A R
authors.initials: FAR
authors.lastname: García
authors.affiliation: Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts.|Now with the National Institutes of Health, Bethesda, Maryland (was not affiliated with the National Institutes of Health while a member of the USPSTF).
authors.forename: Matthew W
authors.initials: MW
authors.lastname: Gillman
authors.affiliation: Duke University, Durham, North Carolina.
authors.forename: Alex R
authors.initials: AR
authors.lastname: Kemper
authors.affiliation: Fairfax Family Practice Residency, Fairfax, Virginia.|Virginia Commonwealth University, Richmond.
authors.forename: Alex H
authors.initials: AH
authors.lastname: Krist
authors.affiliation: Yale University, New Haven, Connecticut.
authors.forename: Ann E
authors.initials: AE
authors.lastname: Kurth
authors.affiliation: University of Alabama at Birmingham.
authors.forename: C Seth
authors.initials: CS
authors.lastname: Landefeld
authors.affiliation: University of Missouri, Columbia.
authors.forename: Michael L
authors.initials: ML
authors.lastname: LeFevre
authors.affiliation: University of California, Los Angeles.
authors.forename: Carol M
authors.initials: CM
authors.lastname: Mangione
authors.affiliation: University of Washington, Seattle.
authors.forename: William R
authors.initials: WR
authors.lastname: Phillips
authors.affiliation: Stanford University, Stanford, California.
authors.forename: Douglas K
authors.initials: DK
authors.lastname: Owens
authors.affiliation: Brown University, Providence, Rhode Island.
authors.forename: Maureen G
authors.initials: MG
authors.lastname: Phipps
authors.affiliation: University of Texas at Austin.
authors.forename: Michael P
authors.initials: MP
authors.lastname: Pignone
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D002318:Cardiovascular Diseases / Q000401:mortality / Q000517:prevention & control*; D050171:Dyslipidemias / Q000150:complications / Q000175:diagnosis / Q000178:diet therapy*; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects*; D008297:Male; D008403:Mass Screening / Q000592:standards; D008875:Middle Aged; D011322:Primary Prevention; D018570:Risk Assessment
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors